The ISTH DIC-score predicts early mortality in patients with non-promyelocitic acute myeloid leukemia

coagulation disorders frequently complicate the clinical course of acute myeloid leukemia (AML) patients. this study examined the frequency and prognostic significance, with regards of early mortality, of the presence of overt disseminated intravascular coagulation (DIC) at AML diagnosis and its correlation with clinical and biological characteristics. a retrospective analysis of 351 newly diagnosed non-promyelocytic AML patients was conducted, utilizing the 2018 ISTH DIC-Score criteria to evaluate the presence of overt DIC at AML onset. the study cohort had a median age of 65 years with a predominance of male gender (59%). overt DIC was present in 21% of cases and was associated with advanced age, comorbidities, poor performance status, hyperleukocytosis, LDH levels, NPM1 mutations, expression of CD33 and CD4, and lack of expression of CD34. With a median follow-up of 72 months (3–147 months), the 6-year overall survival (OS) was 17.4%, with patients having overt DIC showing significantly poorer outcomes (7.2% compared to 20.3 % of those without DIC, p < 0.001). patients with overt DIC showed markedly high early mortality rates at 30 (42.5% vs 8 %), 60 (49.3% vs 16.9%), and 120 days (64.4% vs 25.6%) from disease onset. In multivariate analysis overt DIC retained its independent prognostic value for early mortality. In conclusion, the prevalence and clinical relevance of DIC in non-promyelocytic AML is not negligible, underlining its potential as an unfavorable prognostic marker. In newly diagnosed patients with AML, early recognition and measure to counteract coagulation disturbances might help mitigate the elevated mortality risk associated with DIC.